PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
43.99
+1.16 (+2.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close42.83
Open42.64
Bid0.00 x 900
Ask0.00 x 1200
Day's Range42.64 - 44.10
52 Week Range27.53 - 48.99
Volume229,119
Avg. Volume781,366
Market Cap2.57B
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-3.61
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.29
Trade prices are not sourced from all markets
  • GuruFocus.com9 days ago

    5 Health Care Stocks in Gurus' Portfolios

    PTC Therapeutics makes the list

  • Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study
    Zacks18 days ago

    Pfizer's DMD Gene Therapy Shows Severe Side Effects in Study

    Pfizer (PFE) presents early data from a study on its investigational gene therapy for DMD. However, the study highlighted some serious side effects in two out of the six participants.

  • PR Newswire18 days ago

    PTC Therapeutics Announces Strategic Gene Therapy Licensing Agreement with Odylia Therapeutics

    - Collaboration expands PTC's Gene Therapy portfolio to rare ophthalmic diseases - SOUTH PLAINFIELD, N.J. and BOSTON , July 1, 2019 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics ...

  • PR Newswire21 days ago

    PTC Provides Update on Translarna™ (ataluren) Application for Label Expansion

    SOUTH PLAINFIELD, N.J., June 28, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has completed their review of a proposed indication extension of Translarna™ (ataluren) for the treatment of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) who are non-ambulatory. While the CHMP adopted a negative opinion of the extension, PTC was informed by EMA representatives that the European Public Assessment Report (EPAR) will be updated to clarify that patients who start Translarna while ambulatory are not required to discontinue treatment after loss of ambulation.

  • Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?
    Simply Wall St.last month

    Did You Miss Therapeutics's (NASDAQ:PTCT) Whopping 511% Share Price Gain?

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. But when you...

  • Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On PTC Therapeutics, Inc. (PTCT)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Benzingalast month

    PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

    PTC Therapeutics, Inc. (NASDAQ: PTCT ) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy ...

  • PR Newswirelast month

    PTC Therapeutics Receives FDA Approval for the Expansion of the EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

    SOUTH PLAINFIELD, N.J., June 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Emflaza® (deflazacort) to expand its labeling to include patients with Duchenne muscular dystrophy who are between 2- and 5-years-old. Emflaza was first approved by the FDA in February 2017 for the treatment of Duchenne in patients 5-years and older.

  • PTC Therapeutics Promotes Emily Hill to Chief Financial Officer
    PR Newswire2 months ago

    PTC Therapeutics Promotes Emily Hill to Chief Financial Officer

    SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November ...

  • PR Newswire2 months ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on May 20, 2019 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • PR Newswire2 months ago

    PTC Therapeutics to Participate at Upcoming Investor Conference

    SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, ...

  • PR Newswire2 months ago

    PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders

    SOUTH PLAINFIELD, N.J., May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year's funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.

  • PR Newswire2 months ago

    PTC Therapeutics and MRI Interventions Announce Strategic Investment

    SOUTH PLAINFIELD, N.J. and IRVINE, Calif., May 9, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) and MRI Interventions, Inc. (MRIC) today announced a strategic equity investment, with PTC purchasing $4.0 million in shares of MRI common stock. PTC and MRI have also entered into a supply agreement for MRI's neurosurgical devices for PTC's current and future gene therapy programs. MRI is a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene therapy.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PTCT earnings conference call or presentation 2-May-19 8:30pm GMT

    Q1 2019 PTC Therapeutics Inc Earnings Call

  • PR Newswire2 months ago

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill ...

  • This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen
    Investor's Business Daily2 months ago

    This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen

    PTC Therapeutics and Roche's spinal muscular atrophy treatment showed positive test results early Tuesday — leading shares of rival Ionis Pharmaceuticals and Biogen to slide.

  • PR Newswire2 months ago

    Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

    Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing 58% of patients experienced an improvement of at least 3 points on MFM32 scale vs. baseline after ...

  • PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates
    Zacks3 months ago

    PTC Therapeutics (PTCT) Reports Q1 Loss, Lags Revenue Estimates

    PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -22.97% and -24.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    PTC Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of $1.29. Losses, adjusted for non-recurring costs, came to 91 cents per share. The biopharmaceutical company posted ...

  • PR Newswire3 months ago

    PTC Therapeutics Reports First Quarter 2019 Financial Results and Provides a Corporate Update

    SOUTH PLAINFIELD, N.J., May 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2019. "We believe we are making great strides towards our vision of having many more treatments for patients of rare disorders," said Stuart Peltz, Ph.D., CEO of PTC Therapeutics.  "The approval of Translarna expands our footprint in Brazil. Translarna received approval from the Brazilian health regulatory authority (ANVISA) which will allow for expanded market access.

  • Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT)
    Insider Monkey3 months ago

    Here is What Hedge Funds Think About PTC Therapeutics, Inc. (PTCT)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • PR Newswire3 months ago

    Translarna™ (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy

    SOUTH PLAINFIELD, N.J., April 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval from the Brazilian National Health Surveillance Agency (ANVISA) under rare diseases procedure, for the treatment of ambulatory children five years and older with Duchenne muscular dystrophy caused by a nonsense mutation. Primarily affecting males, Duchenne muscular dystrophy is a rare, irreversible, and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-twenties due to heart and respiratory failure.

  • Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

    PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire3 months ago

    PTC Therapeutics to Host Conference Call to Discuss First Quarter 2019 Financial Results

    SOUTH PLAINFIELD, N.J. , April 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2019 financial ...